Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.89 Analyst target: $3.63 Upside: 305.30%
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.
See the full interactive analysis & chart →Informational only — not investment advice.